Content reviewed by clinical research staff
Evidence graded using the PeptideScholar A-D system
Semaglutide
AFDA ApprovedGLP-1 receptor agonist · 31 amino acids · Brand: Ozempic, Wegovy, Rybelsus
Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). One of the most studied peptide drugs in recent history.
Mechanism of Action
Mimics endogenous GLP-1, binding to GLP-1 receptors in the pancreas, gut, and brain. Enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via hypothalamic signaling.
Benefits
- Mean 15% body weight loss in obesity trials (STEP 1)
- Significant HbA1c reduction in type 2 diabetes
- Reduced major cardiovascular events (SELECT trial)
- Available in oral formulation (Rybelsus)
Side Effects
- Nausea and vomiting (especially during titration)
- Diarrhea or constipation
- Pancreatitis risk (rare)
- Gallbladder disorders
- Potential thyroid C-cell tumor risk (animal studies)
Ready to Discuss Semaglutide with a Doctor?
Semaglutide is FDA-approved and available by prescription. Licensed telehealth providers can evaluate if it's right for you.
Find a Prescribing ProviderTelehealth consultations available in most states
PeptideScholar may receive compensation from provider referrals. This does not influence our editorial content.
Research & Evidence
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Semaglutide 2.4 mg produced 14.9% mean body weight loss vs 2.4% with placebo over 68 weeks in 1,961 adults
PMID: 33567185Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6)
Semaglutide reduced major adverse cardiovascular events by 26% vs placebo in type 2 diabetes patients
PMID: 27633186Semaglutide and Cardiovascular Outcomes in Obesity (SELECT)
Semaglutide 2.4 mg reduced major cardiovascular events by 20% in overweight/obese adults without diabetes
PMID: 37385275Compare Semaglutide With
References
- 1. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. “Semaglutide 2.4 mg produced 14.9% mean body weight loss vs 2.4% with placebo over 68 weeks in 1,961 adults” [PMID: 33567185]
- 2. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine, 2016. “Semaglutide reduced major adverse cardiovascular events by 26% vs placebo in type 2 diabetes patients” [PMID: 27633186]
- 3. Semaglutide and Cardiovascular Outcomes in Obesity (SELECT). New England Journal of Medicine, 2023. “Semaglutide 2.4 mg reduced major cardiovascular events by 20% in overweight/obese adults without diabetes” [PMID: 37385275]
Recommended Resources
The Peptide Protocols Handbook
Evidence-based reference guide covering mechanisms, research, and clinical applications.
View on AmazonThird-Party Peptide Testing
Independent lab analysis to verify peptide purity and authenticity.
Learn MoreLinks may be affiliate links. See our disclosure.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.
Related Peptides
Tirzepatide
ATirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FD...
Liraglutide
ALiraglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes ...
Retatrutide
BRetatrutide is an investigational triple-hormone receptor agonist developed by E...
AOD-9604
CAOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) or...
Get Peptide Research Updates
Weekly evidence summaries and regulatory alerts.
No spam. Unsubscribe anytime.